sinc
progress
cirrhosi
acceler
time
complic
recur
manag
treatment
complic
critic
enhanc
qualiti
life
expect
life
patient
use
model
endstag
liver
diseas
incorpor
serumsodium
meldna
physiolog
indic
use
assess
sever
differenti
therapeut
intervent
studi
aim
determin
mean
surviv
period
cumul
surviv
rate
classifi
patient
highrisk
lowrisk
group
base
meldna
predictor
mortal
liver
diseas
investig
mortal
prognost
factor
retrospect
cohort
studi
follow
strobe
checklist
perform
patient
diagnos
liver
cirrhosi
complic
first
time
hospit
select
subject
studi
collect
data
analyz
base
surviv
packag
provid
statist
program
r
version
subject
classifi
highrisk
lowrisk
group
use
meldna
point
sensit
specif
cross
cutoff
point
gender
age
primari
caregiv
signific
variabl
mortal
highrisk
group
ast
albumin
primari
caregiv
signific
variabl
mortal
lowrisk
group
base
mortal
prognost
factor
possibl
present
factor
affect
mortal
patient
diagnos
liver
cirrhosi
complic
first
time
classif
patient
risk
level
could
foundat
provid
accur
guidelin
manag
necessari
modifi
prognost
factor
appli
nurs
intervent
manag
complic
abbrevi
ast
aspart
transferas
meldna
model
endstag
liver
diseas
incorpor
serumsodium
liver
cirrhosi
endstag
chronic
liver
diseas
progress
liver
cirrhosi
hepatocyt
necrosi
present
wide
well
fibrosi
destroy
normal
structur
liver
liver
cirrhosi
rank
lead
caus
mortal
adult
world
korea
liver
diseas
rank
lead
caus
mortal
account
death
per
surviv
rate
patient
cirrhosi
respect
liver
cirrhosi
one
major
diseas
lead
mortal
korea
incid
rate
hepat
b
high
varieti
caus
includ
chronic
hepat
due
hepat
b
viru
hepat
c
viru
consumpt
larg
amount
alcohol
autoimmun
hepat
b
common
case
depend
presenc
complic
progress
liver
cirrhosi
classifi
decompens
cirrhosi
complic
compens
cirrhosi
without
complic
progress
rate
compens
cirrhosi
decompens
cirrhosi
approxim
progress
decompens
cirrhosi
mortal
rate
within
year
becom
without
liver
transplant
complic
could
caus
high
differ
progress
diseas
common
complic
ascit
hepat
encephalopathi
varicos
vein
sinc
progress
cirrhosi
acceler
time
complic
recur
manag
treatment
complic
critic
enhanc
qualiti
life
life
expect
patient
recent
diversif
chronic
diseas
incid
rate
complic
also
risen
manag
complic
higher
influenc
qualiti
life
therefor
would
reason
assum
patient
liver
cirrhosi
presenc
complic
treatment
critic
factor
anticip
degrad
qualiti
life
mortal
liver
transplant
enhanc
qualiti
life
surviv
rate
patient
cirrhosi
howev
numer
patient
given
opportun
liver
transplant
due
lack
donor
indic
progress
prognosi
cirrhosi
model
endstag
liver
diseas
incorpor
serumsodium
meldna
recommend
tradit
childturcottepugh
ctp
use
index
assess
progress
cirrhosi
inpati
sever
cirrhosi
classifi
b
c
base
presenc
ascit
andor
hepat
encephalopathi
serum
bilirubin
prothrombin
period
serum
albumin
use
ctp
point
assign
stage
point
stage
b
point
higher
stage
c
higher
score
sever
get
howev
sinc
subject
judgement
could
involv
judgement
ascit
hepat
encephalopathi
indic
ctp
judgement
sever
use
meld
meldna
becom
import
well
treatment
mediat
base
sever
meldna
assess
serum
bilirubin
prothrombin
period
serum
creatinin
serum
sodium
factor
sinc
meldna
like
predict
mortal
tool
recent
use
creat
wait
list
patient
liver
transplant
studi
prognosi
patient
cirrhosi
mostli
focus
termin
case
anticip
shortterm
mortal
highlight
analysi
prognosi
patient
cirrhosi
rather
classif
patient
consid
level
sever
moreov
analysi
prognost
factor
mortal
patient
includ
diseaserel
factor
also
person
social
factor
analysi
could
provid
comprehens
systemat
understand
patient
diagnos
cirrhot
complic
therefor
studi
patient
diagnos
cirrhot
complic
divid
highrisk
group
lowrisk
group
use
meldna
design
object
physiolog
indic
prognost
factor
analyz
group
aim
devis
selfnurs
method
suitabl
sever
level
liver
cirrhosi
provid
basic
data
improv
effect
manag
chronic
diseas
purpos
studi
check
averag
period
surviv
averag
accumul
rate
surviv
patient
diagnos
ascit
hepat
encephalopathi
varicos
vein
complic
cirrhosi
patient
hospit
complic
first
time
assign
either
group
high
risk
mortal
group
low
risk
mortal
examin
use
meldna
group
mortal
prognost
factor
investig
achiev
follow
done
inform
regard
patient
person
diseas
social
environment
factor
mortal
identifi
cutoff
point
meldna
classifi
patient
either
highrisk
group
lowrisk
group
identifi
inform
regard
person
diseas
social
environment
factor
mortal
highrisk
group
lowrisk
group
identifi
differ
averag
period
surviv
averag
accumul
rate
surviv
high
risk
group
low
risk
group
examin
mortal
prognost
factor
patient
highrisk
group
lowrisk
group
identifi
retrospect
cohort
studi
carri
studi
appli
strobe
checklist
item
studi
approv
appropri
institut
review
board
investig
conform
principl
outlin
declar
helsinki
particip
studi
patient
diagnos
ascit
hepat
encephalopathi
varicos
vein
admit
gener
hospit
locat
seoul
first
time
due
reason
among
patient
admit
hospit
due
complic
cirrhosi
patient
select
base
criteria
state
exclus
criteria
aforement
select
criteria
exclus
criteria
particip
follow
patient
age
older
diagnos
ascit
hepat
encephalopathi
varicos
vein
admit
hospit
first
time
due
reason
b
patient
diagnos
least
one
complic
includ
ascit
hepat
encephalopathi
varicos
vein
exclus
criteria
patient
simultan
diagnos
least
two
complic
includ
ascit
hepat
encephalopathi
varicos
vein
b
patient
histori
complic
liver
cirrhosi
c
patient
diagnos
chronic
renal
failur
malign
tumor
andor
cardiovascular
diseas
time
hospit
patient
underw
liver
transplant
data
collect
period
data
collect
studi
execut
approv
institut
review
board
gener
hospit
patient
diagnos
ascit
hepat
encephalopathi
varicos
vein
admit
gener
hospit
first
time
due
reason
januari
till
decemb
electron
medic
record
januari
till
juli
review
consid
fact
median
surviv
period
cirrhosi
month
data
march
septemb
collect
directli
fill
item
case
record
part
electron
medic
record
variabl
case
record
condit
particip
first
day
hospit
observ
mortal
particip
confirm
medic
record
period
till
date
mortal
consid
surviv
period
particip
surviv
till
end
studi
becam
hospit
studi
stop
hospit
visit
mortal
particip
could
check
data
particip
consid
censor
kim
et
al
meldna
score
score
calcul
use
equat
meld
maximum
minimum
na
meql
respect
collect
data
analys
base
surviv
packag
provid
statist
program
r
version
r
foundat
statist
comput
vienna
austria
detail
method
analysi
follow
distribut
valu
gener
socioenvironment
clinic
factor
analys
use
descript
statist
frequenc
percentag
mean
standard
deviat
calcul
cutoff
point
meldna
score
classifi
highrisk
group
low
risk
group
receiv
oper
characterist
roc
curv
area
curv
auc
calcul
gener
socioenvironment
clinic
factor
mortal
highrisk
group
lowrisk
group
analyz
use
descript
statist
frequenc
percentag
mean
standard
deviat
differ
risk
group
averag
surviv
period
analys
use
test
accumul
surviv
rate
analyz
longrank
test
accumul
surviv
rate
calcul
kaplanmei
estim
analysi
mortal
prognost
factor
particip
risk
group
perform
cox
proport
hazard
regress
model
select
variabl
multivari
analysi
perform
stepwis
select
use
akaik
inform
criterion
aic
schoenfeld
residu
test
perform
gener
socioenvironment
clinic
factor
patient
follow
classifi
particip
group
high
risk
mortal
low
risk
mortal
meldna
use
diagnost
perform
meldna
evalu
auc
criteria
develop
muller
et
al
auc
meldna
studi
diagnost
perform
found
fair
use
tradeoff
point
sensit
singular
meldna
cross
group
high
risk
mortal
group
low
risk
mortal
classifi
score
median
fig
identifi
surviv
period
distribut
curv
analysi
surviv
particip
risk
group
kaplanmeri
estim
use
tabl
surviv
period
distribut
curv
particip
risk
group
shown
figur
shown
figur
could
check
accumul
surviv
rate
decreas
time
particip
highrisk
group
surviv
rate
dramat
decreas
year
followup
accumul
surviv
rate
lowrisk
group
shown
decreas
rather
gradual
signific
differ
accumul
surviv
rate
time
highrisk
group
lowrisk
group
p
tabl
among
variabl
variabl
suitabl
cox
multivari
proport
hazard
regress
model
select
stepwis
select
chosen
select
variabl
select
variabl
mortal
prognost
factor
particip
found
gender
caus
liver
cirrhosi
ctp
stage
marit
statu
primari
caregiv
followup
manag
signific
addit
highrisk
group
gender
age
primari
caregiv
found
signific
ast
albumin
primari
caregiv
signific
variabl
lowrisk
group
detail
given
tabl
numer
variabl
convert
log
risk
rate
calcul
defin
exp
multivari
analysi
mortal
prognost
factor
particip
found
mortal
risk
rate
women
time
lower
men
p
mortal
risk
rate
particip
hepat
c
caus
cirrhosi
time
higher
hepat
b
p
case
ctp
stage
mortal
risk
rate
ctp
stage
b
time
higher
ctp
stage
p
ctp
stage
c
time
higher
ctp
stage
p
particip
whose
primari
care
giver
spous
mortal
risk
rate
time
lower
particip
children
sibl
caregiv
primari
caregiv
primari
caregiv
p
mortal
risk
rate
particip
period
followup
manag
time
lower
irregular
followup
manag
p
multivari
analysi
mortal
prognost
factor
highrisk
group
found
mortal
risk
rate
women
time
lower
men
p
case
age
numer
variabl
mortal
risk
rate
increas
time
sinc
age
increas
year
p
mortal
risk
rate
particip
whose
primari
caregiv
spous
time
lower
particip
other
primari
caregiv
p
multivari
analysi
mortal
prognost
factor
lowrisk
group
found
mortal
risk
rate
increas
time
higher
increas
ast
ul
p
mortal
risk
rate
decreas
time
increas
albumin
gdl
p
mortal
risk
rate
particip
whose
primari
caregiv
spous
time
lower
particip
other
primari
caregiv
p
meldna
object
index
predict
mortal
caus
liver
diseas
wide
use
studi
prognosi
liver
diseas
auc
meldna
studi
found
rel
lower
studi
howev
accord
suggest
muller
et
al
diagnost
perform
rang
goodexcel
would
attribut
significantli
longer
followup
period
year
studi
followup
period
month
rel
lower
auc
studi
might
includ
data
even
case
censor
followup
period
order
reduc
bia
result
cutoff
point
meldna
studi
rel
lower
studi
previou
studi
focus
patient
endstag
cirrhosi
admit
intens
care
unit
schedul
liver
transplant
studi
focus
patient
diagnos
cirrhosi
complic
could
treat
gener
ward
first
time
would
differ
term
sever
compar
previou
studi
studi
address
patient
rel
low
mortal
rate
less
sever
condit
longer
averag
surviv
period
would
necessari
expand
scope
particip
rais
use
cutoff
point
meldna
sinc
surviv
rate
accumul
surviv
rate
studi
found
higher
studi
support
import
manag
complic
futur
would
necessari
studi
surviv
rate
patient
cirrhosi
follow
long
period
make
comparison
studi
longterm
surviv
rate
patient
cirrhosi
confirm
gender
caus
liver
cirrhosi
ctp
stage
marit
statu
primari
caregiv
followup
manag
prognosi
factor
affect
mortal
particip
number
studi
gender
address
import
factor
caus
cirrhosi
also
found
import
predic
mortal
although
differ
hepat
b
hepat
c
could
attribut
also
support
rapid
treatment
viral
hepat
might
affect
prognosi
earli
administr
antivir
drug
import
reduc
incid
cirrhosi
diseaserel
mortal
due
recent
diversif
hepat
antivir
drug
would
tabl
cumul
surviv
rate
patient
liver
cirrhosi
complic
n
high
risk
meldna
n
low
risk
meldna
n
would
necessari
devis
specif
plan
rais
rate
administr
antivir
drug
ctp
point
stage
import
factor
predict
mortal
studi
support
among
variou
signific
prognost
factor
patient
cirrhosi
ctp
score
claim
signific
variabl
therefor
despit
critic
ctp
point
subject
tool
still
import
index
determin
prognosi
cirrhosi
modifi
chilepugh
classif
use
reduc
critic
ctp
score
take
account
chang
patient
conscious
depress
disorient
confus
howev
hematolog
valu
tabl
multivari
analysi
mortal
prognost
factor
patient
liver
cirrhosi
complic
n
physiolog
indic
reflect
significantli
differ
ctp
remain
unchang
addit
ctp
modifi
chilepugh
classif
indocyanin
green
icg
test
meld
meldna
meld
serum
sodium
ratio
meso
examin
mortal
predictor
accuraci
vari
patient
depend
presenc
complic
andor
variabl
necess
compar
studi
mortal
predict
tool
constantli
emphas
would
also
import
discuss
patientreport
outcom
pro
could
affect
qualiti
life
patient
addit
would
also
help
use
variou
tool
simultan
accur
predict
marit
statu
primari
caregiv
import
predictor
especi
aspect
nurs
sinc
studi
relationship
mortal
prognosi
primari
caregiv
patient
cirrhosi
possibl
direct
comparison
studi
selfmanag
diseas
recipi
liver
transplant
famili
relationship
found
factor
affect
selfmanag
diseas
famili
support
cohabit
shown
import
variabl
selfmanag
diseas
patient
chronic
diseas
therefor
famili
support
could
affect
selfmanag
diseas
well
progress
prognosi
diseas
sinc
patient
spous
constantli
seek
patient
need
commun
exchang
emot
patient
presenc
spous
could
affect
diseas
selfmanag
patient
result
studi
also
support
import
spous
support
suggest
import
particip
spous
treatment
patient
lowrisk
group
signific
differ
ast
albumin
studi
also
support
bilirubin
albumin
pt
other
mortal
predictor
patient
cirrhosi
howev
shown
systemat
review
damico
et
al
sinc
studi
address
ast
would
necessari
consid
variou
laboratori
result
laboratori
result
signific
mortal
predictor
highrisk
group
includ
classif
criterion
includ
abnorm
result
sinc
patient
high
risk
mortal
hand
case
lowrisk
group
laboratori
result
like
indic
normal
condit
chang
laboratori
result
could
signific
influenc
mortal
risk
rate
therefor
patient
earli
stage
cirrhosi
laboratori
result
import
also
import
understand
critic
monitor
correct
laboratori
result
treatment
diseas
highrisk
group
age
shown
import
variabl
support
result
averag
age
year
age
becom
import
mortal
predictor
patient
year
old
fact
import
risk
factor
differ
among
risk
group
clinic
import
mean
classif
patient
risk
level
could
foundat
provid
accur
guidelin
diseas
manag
furthermor
classif
could
foundat
patient
cirrhosi
earli
detect
mortal
prognosi
time
manag
complic
critic
correct
prognost
factor
appli
proper
nurs
intervent
studi
signific
given
appli
meldna
patient
diagnos
cirrhosi
complic
first
time
examin
cutoff
point
classifi
patient
base
risk
diseas
investig
risk
factor
risk
group
furthermor
examin
prognost
factor
populationsoci
perspect
medic
perspect
sinc
studi
collect
data
singl
center
would
appropri
gener
result
henc
would
necessari
conduct
multicent
replic
studi
addit
studi
analysi
surviv
mortal
prognost
factor
patient
diseas
complic
cirrhosi
perspect
nurs
would
benefici
patient
diagnos
complic
cirrhosi
first
time
found
gender
caus
liver
cirrhosi
ctp
stage
marit
statu
primari
caregiv
followup
manag
variabl
affect
mortal
prognosi
well
gender
age
primari
caregiv
highrisk
group
ast
albumin
primari
caregiv
lowrisk
group
sinc
studi
analyz
mortal
prognost
factor
analysi
surviv
patient
cirrhosi
would
possibl
varieti
studi
factor
surviv
mortal
patient
perspect
nurs
analysi
surviv
variou
diseas
especi
base
result
studi
nurs
patient
diagnos
complic
cirrhosi
first
time
earli
detect
mortal
prognost
factor
would
possibl
earli
detect
could
allow
correct
factor
might
promot
mortal
well
prevent
recurr
complic
provis
nurs
intervent
help
progress
diseas
patient
